Loading clinical trials...
Loading clinical trials...
Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Discontinuation: a Quasi-experimental Study
Conditions
Interventions
Review the use of mirabegron and its discontinuation
Start Date
January 1, 2017
Primary Completion Date
December 31, 2017
Completion Date
December 31, 2017
Last Updated
November 7, 2018
NCT04873037
NCT06198439
NCT06769854
NCT03535857
NCT06616675
NCT05719285
Lead Sponsor
Catalan Institute of Health
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions